PMID- 31294931
OWN - NLM
STAT- MEDLINE
DCOM- 20200427
LR  - 20231012
IS  - 1758-2652 (Electronic)
IS  - 1758-2652 (Linking)
VI  - 22
IP  - 7
DP  - 2019 Jul
TI  - Switch to dolutegravir is well tolerated in Thais with HIV infection.
PG  - e25324
LID - 10.1002/jia2.25324 [doi]
LID - e25324
AB  - INTRODUCTION: Dolutegravir (DTG) is recommended as part of first-line 
      antiretroviral therapy (ART) for people living with HIV(PLHIV). We sought to 
      determine the rate of adverse events (AEs) and discontinuations among Thais 
      treated during acute HIV infection (AHI) and switched to DTG-based regimens. 
      METHODS: Thai participants in the SEARCH010/RV254 cohort who initiated ART during 
      AHI and switched to DTG for at least 48 weeks were prospectively observed and 
      included in the analysis. Rates and characteristics of DTG-related AEs and 
      discontinuations were described. RESULTS: A total of 313 Thai participants were 
      included in the analysis. The median age was 29 years, 96% were male, 64% had a 
      Bachelor's degree or higher and 16% had a body mass index (BMI) <18.5 kg/m(2) . 
      Participants were on ART for a median of 124 weeks before switching to DTG. The 
      median (IQR) body weight increased from 63 (56 to 70) kg before to 65 (58 to 73) 
      kg (p < 0.0001) after 48 weeks of DTG. Forty-nine (16%) developed DTG-related 
      AEs, corresponding to an incidence of 16.6 per 100 person-years. Neuropsychiatric 
      symptoms were most frequently encountered (n = 25, 8%), followed by laboratory 
      abnormalities (n = 16, 5%). Six (2%) discontinued DTG, corresponding to an 
      incidence of 2.4 per 100 person-years. All discontinuations were due to increased 
      liver enzymes in the presence of hepatitis C virus coinfection. In the 
      multivariate analysis, incident hepatitis C virus infection was the only risk 
      factor for discontinuing DTG (hazard ratio 59.4, 95% CI 8.5 to 297.9, 
      p < 0.0001). Neither low BMI nor concurrent abacavir therapy was associated with 
      discontinuation. CONCLUSIONS: DTG was well tolerated with few discontinuations in 
      this cohort of young men. Incident hepatitis C virus infection was a driver of 
      liver-related AEs leading to discontinuations. In populations at risk, regular 
      testing for hepatitis C virus during ART is recommended to anticipate possible 
      AEs, guide management and improve safety.
CI  - (c) 2019 The Authors. Journal of the International AIDS Society published by John 
      Wiley & Sons Ltd on behalf of the International AIDS Society.
FAU - Goh, Orlanda Q
AU  - Goh OQ
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
AD  - Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
AD  - Duke-National University of Singapore Medical School, Singapore, Singapore.
FAU - Colby, Donn J
AU  - Colby DJ
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Pinyakorn, Suteeraporn
AU  - Pinyakorn S
AD  - The Henry M. Jackson Foundation for the Advancement of Military Medicine, 
      Bethesda, MD, USA.
AD  - United States Military HIV Research Program, Walter Reed Army Institute of 
      Research, Silver Spring, MD, USA.
FAU - Sacdalan, Carlo
AU  - Sacdalan C
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Kroon, Eugene
AU  - Kroon E
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Chan, Phillip
AU  - Chan P
AUID- ORCID: 0000-0002-4071-4409
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Chomchey, Nitiya
AU  - Chomchey N
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Kanaprach, Ratchapong
AU  - Kanaprach R
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Prueksakaew, Peeriya
AU  - Prueksakaew P
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Suttichom, Duanghathai
AU  - Suttichom D
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Trichavaroj, Rapee
AU  - Trichavaroj R
AD  - Department of Retrovirology, Armed Forces Research Institute of Medical Sciences, 
      United States Component, Bangkok, Thailand.
FAU - Spudich, Serena
AU  - Spudich S
AD  - Department of Neurology, Yale University, New Haven, CT, USA.
FAU - Robb, Merlin L
AU  - Robb ML
AD  - The Henry M. Jackson Foundation for the Advancement of Military Medicine, 
      Bethesda, MD, USA.
AD  - United States Military HIV Research Program, Walter Reed Army Institute of 
      Research, Silver Spring, MD, USA.
FAU - Phanuphak, Praphan
AU  - Phanuphak P
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Phanuphak, Nittaya
AU  - Phanuphak N
AUID- ORCID: 0000-0002-0036-3165
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
FAU - Ananworanich, Jintanat
AU  - Ananworanich J
AUID- ORCID: 0000-0003-1369-3224
AD  - SEARCH, The Thai Red Cross AIDS Research Centre, Bangkok, Thailand.
AD  - The Henry M. Jackson Foundation for the Advancement of Military Medicine, 
      Bethesda, MD, USA.
AD  - United States Military HIV Research Program, Walter Reed Army Institute of 
      Research, Silver Spring, MD, USA.
AD  - Department of Global Health, University of Amsterdam, Amsterdam, The Netherlands.
CN  - RV254/SEARCH 010 Study Group
LA  - eng
GR  - UL1 TR001863/TR/NCATS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PL  - Switzerland
TA  - J Int AIDS Soc
JT  - Journal of the International AIDS Society
JID - 101478566
RN  - 0 (Anti-HIV Agents)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (Heterocyclic Compounds, 3-Ring)
RN  - 0 (Oxazines)
RN  - 0 (Piperazines)
RN  - 0 (Pyridones)
RN  - DKO1W9H7M1 (dolutegravir)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Adult
MH  - Anti-HIV Agents/administration & dosage/adverse effects/*therapeutic use
MH  - Cohort Studies
MH  - Dideoxynucleosides/administration & dosage/therapeutic use
MH  - Female
MH  - HIV Infections/*drug therapy/*epidemiology
MH  - HIV-1
MH  - Hepatitis C/drug therapy
MH  - Heterocyclic Compounds, 3-Ring/administration & dosage/adverse 
      effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Oxazines
MH  - Piperazines
MH  - Pyridones
MH  - Risk Factors
MH  - Thailand/epidemiology
MH  - Young Adult
PMC - PMC6621926
OTO - NOTNLM
OT  - HIV
OT  - Asian
OT  - adverse effects
OT  - dolutegravir
OT  - hepatitis C
OT  - toxicity
EDAT- 2019/07/12 06:00
MHDA- 2020/04/28 06:00
PMCR- 2019/07/11
CRDT- 2019/07/12 06:00
PHST- 2018/10/07 00:00 [received]
PHST- 2019/05/22 00:00 [accepted]
PHST- 2019/07/12 06:00 [entrez]
PHST- 2019/07/12 06:00 [pubmed]
PHST- 2020/04/28 06:00 [medline]
PHST- 2019/07/11 00:00 [pmc-release]
AID - JIA225324 [pii]
AID - 10.1002/jia2.25324 [doi]
PST - ppublish
SO  - J Int AIDS Soc. 2019 Jul;22(7):e25324. doi: 10.1002/jia2.25324.